1,000 Stem‑Cell Transplants Offer New Hope to Thalassemia Children

When Muhammad Shaheem was barely five months old, a routine check revealed he suffered from severe thalassemia. From that point on, his days were punctuated by regular blood transfusions, a regimen that, over the years, left his heart and liver burdened with iron overload.

Doctors warned that a stem‑cell transplant would be a high‑risk gamble, but destiny offered a glimmer of hope from an unlikely source – Shaheem’s own sister, seven‑year‑old Zara, who turned out to be a perfect Human Leukocyte Antigen (HLA) match.

After months of counseling, preparation and nervous anticipation at the Sankalp‑Bhagwan Mahavir Jain Hospital in Bengaluru, the family took the plunge. Their mother, Zareena, who herself lives with thalassemia major, admits the decision was heart‑wrenching, yet she feels the transplant has handed her son a “second chance” at a life less defined by hospital visits.

This personal story is part of a larger narrative. On September 4, Sankalp India Foundation, together with the international nonprofit DKMS and medical partner Cure2Children, marked their 1,000th paediatric stem‑cell transplant for thalassemia.

It isn’t just a number. The journey to this milestone involved navigating steep costs – anywhere between ₹12 lakh and ₹40 lakh per procedure – and the logistical challenges of finding suitable donors. DKMS alone has funded the transplant expenses for more than 820 children, while Sankalp runs 30 thalassemia day‑care centres serving over 3,000 patients and operates bone‑marrow transplant units in Bengaluru and Ahmedabad.

Rajat Kumar Agarwal, president of Sankalp India Foundation, reflects on the achievement: “Reaching 1,000 transplants is not merely a statistic; it symbolizes countless families who can now look beyond endless transfusions toward a future where thalassemia no longer dictates the rhythm of their lives.”

For families like Shaheem’s, the transplant is more than a medical procedure – it is a rebirth. Post‑transplant monitoring shows promising signs: reduced transfusion dependence, gradual iron recovery, and a glimmer of normalcy returning to schoolrooms and playgrounds.

While challenges persist – especially in scaling donor registries and subsidising costs for the poorest – the collaborative model of NGOs, hospitals and international donors offers a replicable blueprint. As India continues to grapple with one of the world’s highest thalassemia burdens, milestones such as this one‑thousandth transplant remind us that coordinated effort can indeed rewrite destiny.